Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gold Fields Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.86 (market cap $4.98B), while Gold Fields Limited trades at $44.66 (market cap $40.79B). The key difference: Gold Fields Limited is far larger — about 8.2× ACADIA Pharmaceuticals Inc.'s market cap, and Gold Fields Limited pays a 5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GFI | |
|---|---|---|
Market Cap | $4.98B | $40.79B |
Sector | Health | Basic Materials |
52-Week High | $30.57 | $61.52 |
52-Week Low | $20.06 | $31.25 |
Enterprise Value | $4.10B | $41.39B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.88, down 0.79% today, with a bullish technical signal supported by moving averages. The company shows strong fundamental momentum with Q2 2026 earnings beating estimates ($0.18 vs. $0.07 expected) and revenue reaching $308 million, up 17% year-over-year. Recent European Commission approval for DAYBUE in Rett syndrome expands market reach, while institutional interest grows with BlackRock acquiring 22.5 million shares in Q2 2026.
The outlook remains positive with analyst consensus price target of $35.08 suggesting 21% upside potential. Key opportunities include DAYBUE's European expansion and upcoming Alzheimer's data, while risks involve execution challenges and competitive pressures. The stock presents a compelling growth story with 70% analyst buy ratings supporting the bullish thesis.
Gold Fields (GFI) trades at $44.87, down 2.37% on the day, amid a bullish technical setup and strong fundamentals. The company reported robust 2025 results with revenue surging to $8.75B and net income reaching $3.57B, driving a net income margin of 40.76%. Analyst consensus is a Buy with a $52.00 price target, though recent earnings have missed expectations. Positive news includes a doubled interim dividend and a $500M shareholder return plan announced in August 2026.
The outlook for GFI is positive, supported by high gold prices and operational growth, but risks include earnings volatility and debt levels. Investment opportunity lies in its attractive valuation (P/E 9.44) and shareholder returns, yet investors face headwinds from cost inflation and geopolitical factors affecting gold markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
